X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs FULFORD INDIA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA FULFORD INDIA SUN PHARMA/
FULFORD INDIA
 
P/E (TTM) x 25.8 398.8 6.5% View Chart
P/BV x 2.7 6.2 43.7% View Chart
Dividend Yield % 0.5 0.1 548.8%  

Financials

 SUN PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
FULFORD INDIA
Mar-14
SUN PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs701942 74.4%   
Low Rs433450 96.3%   
Sales per share (Unadj.) Rs110.4691.4 16.0%  
Earnings per share (Unadj.) Rs11.011.5 95.8%  
Cash flow per share (Unadj.) Rs17.215.4 112.2%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.3 122.8%  
Book value per share (Unadj.) Rs158.8380.0 41.8%  
Shares outstanding (eoy) m2,399.263.90 61,519.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.0 510.0%   
Avg P/E ratio x51.660.7 85.0%  
P/CF ratio (eoy) x32.945.3 72.6%  
Price / Book Value ratio x3.61.8 194.9%  
Dividend payout %18.217.4 104.4%   
Avg Mkt Cap Rs m1,360,0212,714 50,103.9%   
No. of employees `00017.80.4 4,006.5%   
Total wages/salary Rs m53,671505 10,627.8%   
Avg. sales/employee Rs Th14,890.96,073.0 245.2%   
Avg. wages/employee Rs Th3,017.11,137.4 265.3%   
Avg. net profit/employee Rs Th1,480.6100.7 1,470.6%   
INCOME DATA
Net Sales Rs m264,8952,696 9,824.0%  
Other income Rs m8,388125 6,688.7%   
Total revenues Rs m273,2822,822 9,684.7%   
Gross profit Rs m56,081-46 -120,864.9%  
Depreciation Rs m14,99815 98,673.7%   
Interest Rs m5,17610 54,481.1%   
Profit before tax Rs m44,29554 81,574.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,45210 88,040.6%   
Profit after tax Rs m26,33845 58,921.5%  
Gross profit margin %21.2-1.7 -1,230.3%  
Effective tax rate %19.117.7 107.9%   
Net profit margin %9.91.7 599.8%  
BALANCE SHEET DATA
Current assets Rs m316,3591,738 18,199.3%   
Current liabilities Rs m198,643545 36,468.4%   
Net working cap to sales %44.444.3 100.4%  
Current ratio x1.63.2 49.9%  
Inventory Days Days9548 195.6%  
Debtors Days Days1084 2,501.7%  
Net fixed assets Rs m213,17812 1,791,412.6%   
Share capital Rs m2,39939 6,152.1%   
"Free" reserves Rs m378,6061,443 26,237.4%   
Net worth Rs m381,0061,482 25,708.9%   
Long term debt Rs m17,7210-   
Total assets Rs m643,0282,077 30,963.9%  
Interest coverage x9.66.7 142.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.41.3 31.7%   
Return on assets %4.92.6 187.8%  
Return on equity %6.93.0 229.2%  
Return on capital %10.04.3 232.8%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m40,81617 237,304.7%   
Fx outflow Rs m30,143673 4,477.9%   
Net fx Rs m10,673-656 -1,627.1%   
CASH FLOW
From Operations Rs m39,07290 43,412.8%  
From Investments Rs m-33,708105 -32,225.7%  
From Financial Activity Rs m-15,393-14 109,167.4%  
Net Cashflow Rs m-7,359181 -4,077.1%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 3.8 135.0%  
FIIs % 23.0 0.1 23,000.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.2 39.2%  
Shareholders   133,026 4,783 2,781.2%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  WOCKHARDT LTD.  SHASUN PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 22, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS